President Trump announced FDA Commissioner Marty Makary's departure on Tuesday, replacing him with Jones Day partner Kyle Diamantas as acting head. The White House cited Makary's difficulties in the role, though sources indicated clashes with anti-abortion advocates influenced the decision.

Makary's exit leaves both the FDA and CDC without permanent leadership during a critical period marked by hantavirus outbreak concerns. The commissioner had previously resisted pressure from conservative groups, drawing praise from Democratic Senator Dick Durbin for standing up to the administration. Republican Senator Josh Hawley welcomed the change, calling Makary "uniquely destructive to the pro-life movement."

The leadership vacuum has rattled biotech investors already concerned about regulatory uncertainty. The industry's main lobbying group warned that constant turmoil undermines confidence in drug approvals. Multiple FDA divisions now operate under acting heads, creating unprecedented instability at the agency responsible for approving new medicines.

Diamantas brings legal experience from representing Abbott Laboratories during infant formula litigation, but lacks the pharmaceutical expertise that biotech companies seek in permanent FDA leadership. The appointment signals continued disruption for an agency central to drug development timelines and market valuations.